Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer

• Published in: Cancer Vol. 126; no. 17; pp. 3972 - 3981
• Main Authors: Hanna, Glenn J., Guenette, Jeffrey P., Chau, Nicole G., Sayehli, Cyrus M., Wilhelm, Christian, Metcalf, Robert, Wong, Deborah J., Brose, Marcia, Razaq, Mohammad, Pérez‐Ruiz, Elisabeth, Cohen, Ezra E. W., Aggarwal, Rahul, Scholz, Catherine, Gualberto, Antonio, Ho, Alan L.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2020
• Subjects: Adult; Aged; Cancer; Confidence intervals; Disease control; Female; Gene frequency; Histology; HRAS; Humans; Male; Metastases; Metastasis; Middle Aged; Mutants; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - pathology; Oncology; Oral cancer; Patients; Progression-Free Survival; Proto-Oncogene Proteins p21(ras) - genetics; Quinolones - administration & dosage; Quinolones - adverse effects; rare cancers; salivary cancer; Salivary gland; Salivary Gland Neoplasms - drug therapy; Salivary Gland Neoplasms - genetics; Salivary Gland Neoplasms - pathology; Salivary glands; Solid tumors; Statistical analysis; Survival; targeted therapy; tipifarnib; Toxicity; Treatment Outcome; Tumors; targeted therapy; tipifarnib; HRAS; rare cancers; salivary cancer

Background To the authors' knowledge, there are no approved therapies for recurrent, metastatic (R/M) salivary gland carcinoma (SGC), but molecularly targeted therapies warrant ongoing investigation. In the current study, the authors have reported on the efficacy of tipifarnib in patients with...